The ongoing development of new indications for GLP-1 drugs offers promising prospects for further expanding therapeutic interventions, showcasing their significant potential in the medical field
In vivo safety assessment Healthy mice received a topical application of OA-NPs@OA or free OA (at a high dose of 1 mg per mouse) to their shaved dorsal skin twice daily for 7 consecutive days
In dermatology and trichology research, it is often combined with other copper-binding or Wnt-active peptides as a single topical formulation
Injection-site reactions Mild redness or swelling at the injection site is common, especially during early titration
a recent safety analysis found no anaphylaxis in hundreds of patients receiving high-dose IV thiamine, suggesting the risk is very low in practice
Dihexa or its analogs were administered 5 minutes after scopolamine, either intracerebroventricularly at doses of 0.1 or 1 nmol), intraperitoneally at doses of 0.05, 0.25, or 0.50 mg/kg, or orally at doses of 1.25 or 2.0 mg/kg